Overview

A Study of AK104（ an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer

Status:
Not yet recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, phase II clinical study conducted in China. All subjects will receive AK104 in combination with standard treatment regimens or AK104 alone. The primary end points are objective response rate per RECIST1.1 and safety. Secondary end points are progression-free survival and disease control rate.

Phase:

Phase 2

Details

Lead Sponsor:

Akeso

Treatments:

Bevacizumab
Carboplatin
Paclitaxel